• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home StudyGraphics

#VisualAbstract Oral azacitidine (CC-486) plus R-CHOP shows an acceptable safety profile in untreated diffuse large B-cell lymphoma

byKathleen Lau
March 3, 2022
in StudyGraphics
Reading Time: 1 min read
0
Share on FacebookShare on Twitter

RELATED REPORTS

Incyte: Monjuvi improves survival in patients with relapsed or refractory follicular lymphoma

#Visual Abstract: Targeted Agents Combined with CHOP Increased Response Rates for Peripheral T-Cell Lymphoma

#VisualAbstract: Irinotecan and Temozolomide Plus Dasatinib and Rapamycin Improved Progression-Free Survival for Relapsed or Refrcatory Neuroblastoma

Tags: azacitidineB-cell lymphomaDiffuse large B-cell lymphoma (DLBCL)dose escalationfollicular lymphomaprogression-free survivalR-CHOP
Previous Post

Novavax vaccine is safe and effective for prevention of Covid-19

 Next Post

Most young people do not meet the three 24-Hour Movement Guidelines

RelatedReports

No clinical benefit of specific immunotherapy seen in lymphoma
Pharma

Incyte: Monjuvi improves survival in patients with relapsed or refractory follicular lymphoma

January 10, 2025
#Visual Abstract: Targeted Agents Combined with CHOP Increased Response Rates for Peripheral T-Cell Lymphoma
StudyGraphics

#Visual Abstract: Targeted Agents Combined with CHOP Increased Response Rates for Peripheral T-Cell Lymphoma

August 8, 2024
#VisualAbstract: Irinotecan and Temozolomide Plus Dasatinib and Rapamycin Improved Progression-Free Survival for Relapsed or Refrcatory Neuroblastoma
StudyGraphics

#VisualAbstract: Irinotecan and Temozolomide Plus Dasatinib and Rapamycin Improved Progression-Free Survival for Relapsed or Refrcatory Neuroblastoma

July 26, 2024
#VisualAbstract: Oral azacitidine did not improve progres-sion-free survival but had a better safety profile for follicular helper T-cell lymphoma
StudyGraphics

#VisualAbstract: Oral azacitidine did not improve progres-sion-free survival but had a better safety profile for follicular helper T-cell lymphoma

June 7, 2024
Next Post
African American and Hispanic youth more likely to discontinue ADHD treatment

Most young people do not meet the three 24-Hour Movement Guidelines

Family presence during CPR associated with lower rates of emotional trauma

Pediatric emergency simulation training strengthens team performance and learner confidence, may improve outcomes

Racial, ethnic differences in outcomes of extremely preterm infants decreasing but persistent

Enteral insulin reduces the duration of feeding intolerance in preterm infants

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Early screening for emotional and cognitive issues may improve psychiatric outcomes for stroke patients
  • Artificial intelligence may assist in early detection of decreased ejection fraction on echocardiograms
  • #VisualAbstract: Tarlatamab Improves Survival in Small-Cell Lung Cancer after Platinum-Based Chemotherapy
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
No Result
View All Result

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.